Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
Multiple Sclerosis and Related Disorders|November 20, 2019
Infusion-related reactions during Natalizumab treatment: Do we still need a post-infusion observation period?R Sacco, G Disanto, I Maraffi, et al.
Expert Opinion on Biological Therapy|April 5, 2015
Natalizumab in spinal multiple sclerosis in a daily clinical settingChiara Zecca, Mirjam R Heldner, Christian P Kamm, et al.
Neurochemistry International|June 6, 2008
Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosisJohann Sellner, Isabell Greeve, Oliver Findling, et al.
PLOS Digital Health|November 6, 2024
Real-world patterns in remote longitudinal study participation: A study of the Swiss Multiple Sclerosis RegistryPaola Daniore, Chuqiao Yan, Mina Stanikic, et al.
Multiple Sclerosis and Related Disorders|April 17, 2023
Experiences of persons with multiple sclerosis with the Covid-19 vaccination: A cross-sectional study of the Swiss Multiple Sclerosis RegistryMina Stanikić, Eric Twomey, Milo A Puhan, et al.
European Journal of Neurology|February 13, 2018
Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosisC Zecca, S Roth, O Findling, et al.
BMJ Neurology Open|September 26, 2025
Real-world use of disease-modifying therapy in persons with multiple sclerosis aged 55 and overMina Stanikić, Anke Salmen, Christian P Kamm, et al.
Vaccines|June 24, 2022
Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis PatientsHelly Hammer, Robert Hoepner, Christoph Friedli, et al.
Biomed Research International|February 18, 2016
Characterization of Enhancing MS Lesions by Dynamic Texture Parameter Analysis of Dynamic Susceptibility Perfusion ImagingRajeev K Verma, Johannes Slotboom, Cäcilia Locher, et al.
Pageof 9